Skip to main content
Figure 4 | BMC Biotechnology

Figure 4

From: Secretory expression of biologically active human Herpes virus interleukin-10 analogues in Escherichia colivia a modified Sec-dependent transporter construct

Figure 4

Inhibition of LPS-induced TNF-α release by E. coli derived recombinant EBV IL-10. J774.1 mouse macrophages were incubated with E. coli BL21 (DE3) pGA6 periplasmic fraction alone (bacterial recombinant EBV IL-10 at ~ 400 ng/ml) or in the presence of neutralizing monoclonal anti-EBV IL-10 antibody. Periplasmic fractions of E. coli BL21 (DE3) pUC19 were used as TNF-α induction control. Commercial EBV IL-10 (at ~ 400 ng/ml) served as positive control. TNF-α induction levels were set at 100%, and changes of TNF-α release are the means ± SD of four independent experiments. Statistical significance was determined using the Student t-test. Asterisks indicate statistically significant differences (* p ≤ 0.05; ** p ≤ 0.01) between pGA6 PP, pUC19 PP, and pGA6 after anti-EBV IL-10 treatment. PP = periplasmic fraction; Com. = commercial; Rec. = recombinant; mAb = monoclonal antibody.

Back to article page

BMC Biotechnology

ISSN: 1472-6750

Contact us